Expression and significance of transforming growth factor-β receptor type II and DPC4/Smad4 in non-small cell lung cancer.

Hong Chen,Jing-Wei Wang,Li-Xin Liu,Shu-Hua Ren,Zheng Lu,Ji-Dong Yan,Yan Li

doi:10.3892/etm.2014.2065

Hong Chen, Jing-Wei Wang + Show 5 more

Open Access

https://doi.org/10.3892/etm.2014.2065

Copy DOI

Abstract

The aim of the present study was to investigate the expression levels of transforming growth factor-β (TGF-β) receptor type II (TβRII) and DPC4/Smad4 in the TGF-β signaling pathway and the importance of these expression levels in non-small cell lung cancer (NSCLC). The mRNA and protein expression levels of TβRII and DPC4/Smad4 were detected by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively, in NSCLC and control nonlesional lung tissues of 60 patients. The protein expression levels of DPC4/Smad4 were detected by immunohistochemistry in paraffin-embedded samples of NSCLC. In addition, the correlations among the expression levels of TβRII and DPC4/Smad4 and their association with the clinical and pathological features of NSCLC were analyzed. The expression levels of TβRII and DPC4/Smad4 in NSCLC tissues were significantly lower when compared with the control nonlesional lung tissues (P<0.05). In addition, the expression of TβRII and DPC4/Smad4 in poorly-differentiated NSCLC tissues was significantly lower compared with moderately- or well-differentiated NSCLC tissues (P<0.05). The expression levels of TβRII and DPC4/Smad4 were significantly lower in NSCLC tissues with metastatic lymph nodes compared with tissue without metastatic lymph nodes (P<0.05). Thus, the expression levels were demonstrated to significantly correlate with the clinical and pathological stages, and subsequently were shown to be associated with the occurrence and progression of NSCLC. In conclusion, TβRII and DPC4/Smad4 may play an important role in the tumorigenesis, differentiation and progression of NSCLC via the TGF-β signaling pathway.

Highlights

Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related mortality worldwide, accounting for 80‐85% of lung cancer cases [1]
reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) analysis demonstrated that the relative expression of TβRII in NSCLC tissues was 0.498±0.198, which was markedly lower compared with the control nonlesional lung tissues (1.820±0.672; P
The western blotting results demonstrated that the relative expression of TβRII was 0.203±0.142 in the NSCLC tissues and 0.882±0.334 in the control nonlesional lung tissues, revealing a statistically significant difference (P

Summary

Introduction

Non‐small cell lung cancer (NSCLC) is the leading cause of cancer‐related mortality worldwide, accounting for 80‐85% of lung cancer cases [1]. Transforming growth factor‐β (TGF‐β) plays a critical role in regulating the proliferation, differentiation and apoptosis of cells, as well as the development of embryos. The TGF‐β family includes several isoforms (TGF‐β 1, 2 and 3), which interact with the specific cellular serine/threonine kinase receptors, TGF‐β receptor type I (TβRI) and type II (TβRII) [2]. The heteromeric complexes of these receptors activate Smad proteins in order to regulate the expression of target genes. Hahn et al [4] identified that a TβRII and/or Smad gene deletion, point mutation or functional inactivation occurs in a variety of tumors

Objectives

Methods

Results

Conclusion